Medical Condition News

RSS

Intervertebral disc repair phase 2 trial update from Mesoblast

Global regenerative medicine company Mesoblast Limited (ASX:MSB) has announced that its Phase 2 clinical trial investigating the use of allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) for non-surgical restoration of degenerated intervertebral discs and treatment of low back pain has enrolled 50% of the total study patients. This rapid rate of enrolment attests to the major unmet medical need and to the relative simplicity of Mesoblast’s non-surgical procedure. Mesoblast expects to complete full enrolment by early third quarter.

17 Apr 2012

CSL Behring commits donations to World Federation of Hemophilia GAP program

To mark World Hemophilia Day 2012, CSL Behring has again committed to making significant financial contributions and donations of clotting factor concentrate to the World Federation of Hemophilia (WFH) Global Alliance for Progress (GAP) program over the period of three years, beginning in 2012. The product donations will be made with medicine having a minimum shelf-life of one year.

17 Apr 2012

More insight into tangled proteins in Alzheimer's disease

In Alzheimer's disease, brain neurons become clogged with tangled proteins. Scientists suspect these tangles arise partly due to malfunctions in a little-known regulatory system within cells. Now, researchers have dramatically increased what they know about this particular regulatory system in mice. Such information will help scientists better understand Alzheimer's and other diseases in humans and could eventually provide new targets for therapies.

17 Apr 2012

Tumor microenvironment contributes critically to drug response

It should be possible to significantly improve the response of common cancers to existing "classical" chemotherapy drugs, say scientists at Cold Spring Harbor Laboratory (CSHL), by introducing agents that alter the interaction of cancer cells with their immediate surroundings, called the tumor microenvironment.

17 Apr 2012

Novel system for 3D reconstruction and examination of tissues at microscopic resolution

Researchers have developed a novel, easy-to-use system for three-dimensional (3D) reconstruction and examination of tissues at microscopic resolution, with the potential to significantly enhance the study of normal and disease processes, particularly those involving structural changes. The new approach, using conventional histopathological methods, is described in the May issue of The American Journal of Pathology.

17 Apr 2012

Inadequate sleep can increase risk of obesity

Can lack of sleep make you fat? A new paper which reviews the evidence from sleep restriction studies reveals that inadequate sleep is linked to obesity. The research, published in a special issue of the The American Journal of Human Biology, explores how lack of sleep can impact appetite regulation, impair glucose metabolism and increase blood pressure.

17 Apr 2012

ImmunoGen commences IMGN529 Phase I trial in NHL

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate.

17 Apr 2012

Coronary stents do not increase risk of heart attack, death in people with metal allergies

Cardiologists have long grappled with how to best manage patients with coronary artery disease who report skin hypersensitivity to nickel or other metal components found in stents -- small tubes placed in narrowed or weakened arteries to help improve blood flow to the heart. But new Mayo Clinic research, published in the April 16, 2012, issue of Circulation: Cardiovascular Interventions, may help allay these concerns.

17 Apr 2012

Individuals with low-quality genes may produce offspring with even more inferior chromosomes

Evolutionary biologists at the University of Toronto have found that individuals with low-quality genes may produce offspring with even more inferior chromosomes, possibly leading to the extinction of certain species over generations.

17 Apr 2012

New study describes therapeutic approach to halt cancer progression

A new study describes a therapeutic approach to halting cancer progression by exploiting a previously unrecognized "addiction" of leukemia cells to specific signaling molecules. The research, published by Cell Press online on April 16th in the journal Cancer Cell, identifies non-classical oncogenes critical for tumor development and survival, and describes a potentially less toxic strategy that selectively targets these molecules.

17 Apr 2012

PDAD patients have much denser accumulations of striatal plaques in the brain

Dementia is a frequent complication of Parkinson's disease (PD), but it is clinically impossible to distinguish PD dementia (PDD), which develops from the progression of the Lewy body pathology that underlies PD, from PD with coexistent Alzheimer's disease.

17 Apr 2012

Study: Kidney cancer growth depends on autophagy

New research at the University of Cincinnati (UC) suggests that kidney cancer growth depends on autophagy, a complex process that can provide cells with nutrients from intracellular sources. Researchers say in certain circumstances autophagy can protect tumor cells from chemotherapy, allowing them to survive for long periods of time in a hidden, dormant, metastatic state.

17 Apr 2012

Brainlab announces first patient procedures with Curve Image Guided Surgery at UCSF

Brainlab, a leader in software-driven medical technology, announced today the first patient procedures with Curve Image Guided Surgery at the University of California San Francisco (UCSF) Medical Center's Neuro-Oncology Clinic.

17 Apr 2012

Northwestern's Stone Institute launches new program to combat mental illnesses at first signs

Early symptoms of major mental illness can be subtle personality changes. Therefore, initial warning signs can often be missed, or even ignored due to conventional wisdom that suggests it's better to wait for true behavioral deterioration and prolonged patterns of abnormality before diagnosing and treating a mental illness. But experts warn that waiting until someone is so ill that the psychological sickness is unmistakable can be detrimental and can lead to long-term health concerns.

17 Apr 2012

UCSF scientists assemble high-value genetic resource to help researchers

One of the ultimate ways of understanding what impact any particular gene has in human health or disease is to disrupt it-knocking it down or wiping it out in a worm, fly or mouse and gauging what happens next. Now scientists at the University of California, San Francisco (UCSF) Diabetes Center and the Gladstone Institute for Cardiovascular Disease have assembled a large publicly available resource to help researchers determine the importance of genes in mice and better gauge what roles they might play in disease.

17 Apr 2012

FDA grants 510(k) clearance for QIAGEN’s molecular detection PCR technology

QIAGEN N.V. today announced that the U.S. Food and Drug Administration (FDA) has granted two 510(k) clearances for its real-time PCR (polymerase chain reaction) instrument Rotor-Gene Q MDx and a compatible test for the detection of Influenza A/B, the artus Infl A/B RG RT-PCR Kit, for in vitro diagnostic use.

From QIAGEN Manchester Limited 17 Apr 2012

MTR can prevent cell death in patients with TBI

Wake Forest Baptist Medical Center researchers seeking a successful treatment for traumatic brain injury have found that the size and extent of damaged tissue can be reduced by using a new device to prevent cell death.

17 Apr 2012

Nurr1 gene plays a fundamental role in neuron survival

Researchers at the Institute of Neurosciences at Universitat Aut-noma de Barcelona (INc-UAB) identified the fundamental role played by the Nurr1 gene in neuron survival associated with synaptic activity. The discovery, published in the Journal of Biological Chemistry, allows scientists to study a new target that could help to understand the relationship between alterations in neural connections, which are known to cause early cognitive deficit, and the neurodegeneration characteristic of Alzheimer's disease.

17 Apr 2012

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

17 Apr 2012

ThromboGenics resubmits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.

17 Apr 2012